Merck Ends Development of Blood Cancer Drug Nemtabrutinib

By Katherine Hamilton

 

Merck is ending the clinical development of nemtabrutinib as an investigational treatment for certain blood cancers.

The drug was being evaluated as a treatment for patients with chronic lymphocytic leukemia, small lymphocytic leukemia and other hematologic malignancies.

Merck said it decided to discontinue a Phase 3 trial following a review of the results that suggested benefits may not outweigh the risks in the study. After a review of further data, it discontinued two other Phase 3 trials with nemtabrutinib.

 

Write to Katherine Hamilton at katherine.hamilton@wsj.com

 

(END) Dow Jones Newswires

November 17, 2026 16:45 ET (21:45 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.

The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.

Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.

Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.

Popular

Sponsor Center